Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | TGM2 | P21980 | 4/20 | 0.35 |
| ▸ | F13A1 | P00488 | 3/20 | 0.35 |
| ▸ | TGM1 | P22735 | 3/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | F12 | P00748 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22718580 | 0.89 | NR1H2 (0.37) | NR1H2ESR2USP2SMN1; SMN2ALDH1A1 | |
| SCHEMBL26645063 | 0.81 | NR1H2 (0.38) | NR1H2ESR2USP2SMN1; SMN2ALDH1A1 | |
| SCHEMBL22718764 | 0.80 | — | — | |
| SCHEMBL22716585 | 0.79 | NR1H2 (0.39) | NR1H2ESR2USP2SMN1; SMN2ALDH1A1 | |
| SCHEMBL22716316 | 0.78 | KRAS (0.33) | NR1H2TGM2F13A1TGM1ESR2 | |
| SCHEMBL16699166 | 0.75 | ADORA1 (0.44) | NR1H2ESR2USP2SMN1; SMN2ALDH1A1 | |
| SCHEMBL26119128 | 0.74 | NR1H2 (0.41) | NR1H2TGM2F13A1TGM1ESR2 | |
| SCHEMBL16711291 | 0.74 | CSNK1E (0.43) | — | |
| SCHEMBL16711450 | 0.74 | CSNK1E (0.52) | — | |
| SCHEMBL26645223 | 0.73 | ALDH1A1 (0.48) | SMN1; SMN2ALDH1A1LMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220242879-A1 | FUSED HETEROCYCLE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2022-08-04 | — | — | US | disclosed |
| US-20220153754-A1 | FUSED HETEROCYCLE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-05-19 | — | — | US | disclosed |
| EP-3976620-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-04-06 | — | — | EP | disclosed |
| EP-3976619-A1 | FUSED HETEROCYCLE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020243153-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153754-A1 | FUSED HETEROCYCLE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | ZC3HAV1, CALM1, ZC3HAV1L | NR1H2 1610/4885TGM2 4226/4885F13A1 512/4885 |
| US-20220242879-A1 | FUSED HETEROCYCLE DERIVATIVES | HAVCR2, HCCS, CYP3A4 | NR1H2 59/4885TGM2 1471/4885F13A1 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.